Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CNS Candidates Mostly Offer New Approaches In Established Categories

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CNS candidates range from new mechanisms in multiple sclerosis to the first orexin antagonist for insomnia and refinements in neurotransmitter targeting for schizophrenia and depression. A second amyloid imaging agent could reach the market to aid in diagnosis of Alzheimer’s disease.

Advertisement

Related Content

CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement
FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
Genzyme Lemtrada’s Momentum Halts With FDA “Refuse-To File” Letter
Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel